Salivary LL-37 Secretion in Individuals with Down Syndrome is Normal
G. Bachrach1,*,
G. Chaushu2,
M. Zigmond1,
E. Yefenof3,
A. Stabholz4,
J. Shapira5,
J. Merrick6, and
S. Chaushu7
1 Institute of Dental Sciences,
3 Lautenberg Center of Immunology,
4 Department of Periodontics,
5 Department of Pediatric Dentistry, and
7 Department of Orthodontics, the Hebrew University-Hadassah School of Dental Medicine, P.O.B. 12272, Jerusalem, Israel 91120;
2 Department of Oral and Maxillofacial Surgery, the Chaim Sheba Medical Center, Tel Hashomer, Israel; and
6 National Institute of Child Health and Human Development, the Office of the Medical Director, Division for Mental Retardation, Ministry of Social Affairs, Israel
View larger version (16K):
[in a new window]
|
Figure 1. Western blot analysis of hCAP18 (18 kDa) and LL-37 (4.5 kDa) in whole (lanes 1–4) vs. parotid (lanes 5–8) saliva. Each lane contains respective saliva samples collected from different (N = 4) control donors.
|
|
View larger version (34K):
[in a new window]
|
Figure 2. Western blot analysis (A) and calculated concentrations (B) of hCAP18 (18 kDa) and LL-37 (4.5 kDa) in whole-saliva samples collected from control (N = 16) and from Down syndrome (N = 24) donors.
|
|
View larger version (10K):
[in a new window]
|
Figure 3. Flow rate of whole saliva (A) and secretion rate of LL-37 (B) and hCAP18 (C) in whole saliva of individuals with Down syndrome (N = 26) vs. healthy controls (N = 16).
|
|
View larger version (6K):
[in a new window]
|
Figure 4. Effect of salivary flow rate on LL-37 concentrations in whole saliva (N = 40).
|
|
Copyright © 2006 Institutional Access Guidelines
